These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37542281)

  • 41. Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu V; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Sep; 33(9):1571-1578. PubMed ID: 28532239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India.
    Seth T; Garg K; Mandal PK; Datta A; Verma S; Hanagavadi S; Thota UR
    Hematology; 2023 Dec; 28(1):2277497. PubMed ID: 37933875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life, self-reported outcomes and impact of education among people with moderate and severe hemophilia A: An integrated perspective from a Latin American country.
    Torres L; Peñuela O; Forero MDR; Satizabal J; Salazar X; Benavides D; Gamarra R; Rivera M; Vizcaya D; Franco JS
    PLoS One; 2023; 18(7):e0287972. PubMed ID: 37410717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study.
    Zhang H; Huang J; Kong X; Ma G; Fang Y
    Health Qual Life Outcomes; 2019 Feb; 17(1):28. PubMed ID: 30728017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial.
    Gomber S; Singhal G; Dewan P; Upreti L; Sikka M
    J Trop Pediatr; 2022 Apr; 68(3):. PubMed ID: 35595254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.
    Noone D; O'Mahony B; van Dijk JP; Prihodova L
    Haemophilia; 2013 Jan; 19(1):44-50. PubMed ID: 22913831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B.
    Booth J; Oladapo A; Walsh S; O'Hara J; Carroll L; Garcia Diego DA; O'Mahony B
    Haemophilia; 2018 Sep; 24(5):e322-e327. PubMed ID: 30091822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
    Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
    Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study.
    Baghaipour M; Salimi T; Bahoush G; Jazebi M; Ala F; Azizi Saraji A; Dorgalaleh A; Moazezi Nekoei Asl SS; Mohamadamini M; Tabibian S
    Transfus Apher Sci; 2021 Dec; 60(6):103212. PubMed ID: 34257016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prophylaxis for severe haemophilia: clinical and economical issues.
    Fischer K; Van Den Berg M
    Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
    Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
    Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.
    Fischer K; Steen Carlsson K; Petrini P; Holmström M; Ljung R; van den Berg HM; Berntorp E
    Blood; 2013 Aug; 122(7):1129-36. PubMed ID: 23777770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
    Liu G; Xin Q; Chen Z; Li L; Chen T; Wu R
    Clin Ther; 2021 Sep; 43(9):1536-1546. PubMed ID: 34392959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.
    Arvanitakis A; Holme PA; Berntorp E; Astermark J
    Haemophilia; 2023 Jul; 29(4):1032-1038. PubMed ID: 37252898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary prophylaxis in children with haemophilia.
    Coppola A; Di Capua M; De Simone C
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s4-11. PubMed ID: 19105503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.